Neurology:帕金森病患者的运动和非运动症状与健康相关的生活质量的关系

2022-06-09 MedSci原创 MedSci原创

潜在的可治疗的运动和非运动症状,特别是神经精神症状,在PwPD的HRQOL的变化中占了很大一部分。

人们对健康相关的生活质量(HRQOL)越来越感兴趣,认为它是对病人福祉的全面展现,是治疗的临床医生的指导概念,也是帕金森病患者(PwPD)的治疗试验结果测量。HRQOL的关键决定因素尚未在大量的PwPD人群中进行调查。为此,来自美国的学者开展了一项在一个大型的帕金森病患者在线队列中评估HRQOL的相关因素的研究。

作为正在进行的在线队列研究的一部分,研究人员对23058名PwPD进行了注册时的横断面分析。对EQ-5D-5L工具测量的HRQOL进行了单变量和逐步多变量的线性回归分析。此外,还进行了交互分析以评估运动症状对HRQOL影响的异质性,并进行了Spearman相关分析以评估非运动症状与HRQOL的关系。

结果显示,在多变量线性回归模型中,有中度或重度抑郁症、更严重的运动症状和更高的合并症负担的参与者,用EQ指数测量的HRQOL下降最多(分别为β-0.11、-0.18、-0.02、-0.01;所有P<0.001)。交互分析显示,更严重的运动症状对女性、低教育水平、低收入、更严重的抑郁症或更严重的认知障碍的人有更大的影响(交互项的p≤0.01)。神经精神症状和跌倒与HRQOL有最大的负相关(ρ -0.31至0.37;p < 0.0001)。

潜在的可治疗的运动和非运动症状,特别是神经精神症状,在PwPD的HRQOL的变化中占了很大一部分。在不同的人口统计学和临床亚群中,运动症状可能对HRQOL有不同的影响,突出了未来健康差异研究的重要领域。

 

参考文献:

Association of Motor and Nonmotor Symptoms With Health-Related Quality of Life in a Large Online Cohort of People With Parkinson Disease.Neurology May 2022, 98 (22) e2194-e2203; DOI: 10.1212/WNL.0000000000200113

评论区 (5)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=1757457, encodeId=60de1e5745767, content=<a href='/topic/show?id=058e4852e63' target=_blank style='color:#2F92EE;'>#帕金森病患者#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=114, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=48527, encryptionId=058e4852e63, topicName=帕金森病患者)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=a17f37322741, createdName=ms6832696159214430, createdTime=Wed Feb 08 21:53:01 CST 2023, time=2023-02-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2001831, encodeId=e1be200183100, content=<a href='/topic/show?id=d5df12695e6' target=_blank style='color:#2F92EE;'>#Neurol#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=96, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=12695, encryptionId=d5df12695e6, topicName=Neurol)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=8217292, createdName=yinhl1978, createdTime=Thu Sep 01 10:53:01 CST 2022, time=2022-09-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1225461, encodeId=d94b1225461f0, content=学习了,谢谢分享, beContent=null, objectType=article, channel=null, level=null, likeNumber=92, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=7c592194322, createdName=1209e435m98(暂无昵称), createdTime=Thu Jun 09 16:31:48 CST 2022, time=2022-06-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1573970, encodeId=eb2515e397040, content=<a href='/topic/show?id=6b3348526a0' target=_blank style='color:#2F92EE;'>#帕金森病患#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=117, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=48526, encryptionId=6b3348526a0, topicName=帕金森病患)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=73fe15977481, createdName=saikp, createdTime=Thu Jun 09 03:53:01 CST 2022, time=2022-06-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1604824, encodeId=dee9160482450, content=<a href='/topic/show?id=950f9419633' target=_blank style='color:#2F92EE;'>#运动症状#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=110, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=94196, encryptionId=950f9419633, topicName=运动症状)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=c33b19274468, createdName=sunrural_42825363, createdTime=Thu Jun 09 03:53:01 CST 2022, time=2022-06-09, status=1, ipAttribution=)]
  2. [GetPortalCommentsPageByObjectIdResponse(id=1757457, encodeId=60de1e5745767, content=<a href='/topic/show?id=058e4852e63' target=_blank style='color:#2F92EE;'>#帕金森病患者#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=114, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=48527, encryptionId=058e4852e63, topicName=帕金森病患者)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=a17f37322741, createdName=ms6832696159214430, createdTime=Wed Feb 08 21:53:01 CST 2023, time=2023-02-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2001831, encodeId=e1be200183100, content=<a href='/topic/show?id=d5df12695e6' target=_blank style='color:#2F92EE;'>#Neurol#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=96, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=12695, encryptionId=d5df12695e6, topicName=Neurol)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=8217292, createdName=yinhl1978, createdTime=Thu Sep 01 10:53:01 CST 2022, time=2022-09-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1225461, encodeId=d94b1225461f0, content=学习了,谢谢分享, beContent=null, objectType=article, channel=null, level=null, likeNumber=92, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=7c592194322, createdName=1209e435m98(暂无昵称), createdTime=Thu Jun 09 16:31:48 CST 2022, time=2022-06-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1573970, encodeId=eb2515e397040, content=<a href='/topic/show?id=6b3348526a0' target=_blank style='color:#2F92EE;'>#帕金森病患#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=117, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=48526, encryptionId=6b3348526a0, topicName=帕金森病患)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=73fe15977481, createdName=saikp, createdTime=Thu Jun 09 03:53:01 CST 2022, time=2022-06-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1604824, encodeId=dee9160482450, content=<a href='/topic/show?id=950f9419633' target=_blank style='color:#2F92EE;'>#运动症状#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=110, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=94196, encryptionId=950f9419633, topicName=运动症状)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=c33b19274468, createdName=sunrural_42825363, createdTime=Thu Jun 09 03:53:01 CST 2022, time=2022-06-09, status=1, ipAttribution=)]
    2022-09-01 yinhl1978
  3. [GetPortalCommentsPageByObjectIdResponse(id=1757457, encodeId=60de1e5745767, content=<a href='/topic/show?id=058e4852e63' target=_blank style='color:#2F92EE;'>#帕金森病患者#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=114, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=48527, encryptionId=058e4852e63, topicName=帕金森病患者)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=a17f37322741, createdName=ms6832696159214430, createdTime=Wed Feb 08 21:53:01 CST 2023, time=2023-02-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2001831, encodeId=e1be200183100, content=<a href='/topic/show?id=d5df12695e6' target=_blank style='color:#2F92EE;'>#Neurol#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=96, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=12695, encryptionId=d5df12695e6, topicName=Neurol)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=8217292, createdName=yinhl1978, createdTime=Thu Sep 01 10:53:01 CST 2022, time=2022-09-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1225461, encodeId=d94b1225461f0, content=学习了,谢谢分享, beContent=null, objectType=article, channel=null, level=null, likeNumber=92, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=7c592194322, createdName=1209e435m98(暂无昵称), createdTime=Thu Jun 09 16:31:48 CST 2022, time=2022-06-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1573970, encodeId=eb2515e397040, content=<a href='/topic/show?id=6b3348526a0' target=_blank style='color:#2F92EE;'>#帕金森病患#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=117, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=48526, encryptionId=6b3348526a0, topicName=帕金森病患)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=73fe15977481, createdName=saikp, createdTime=Thu Jun 09 03:53:01 CST 2022, time=2022-06-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1604824, encodeId=dee9160482450, content=<a href='/topic/show?id=950f9419633' target=_blank style='color:#2F92EE;'>#运动症状#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=110, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=94196, encryptionId=950f9419633, topicName=运动症状)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=c33b19274468, createdName=sunrural_42825363, createdTime=Thu Jun 09 03:53:01 CST 2022, time=2022-06-09, status=1, ipAttribution=)]
    2022-06-09 1209e435m98(暂无昵称)

    学习了,谢谢分享

    0

  4. [GetPortalCommentsPageByObjectIdResponse(id=1757457, encodeId=60de1e5745767, content=<a href='/topic/show?id=058e4852e63' target=_blank style='color:#2F92EE;'>#帕金森病患者#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=114, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=48527, encryptionId=058e4852e63, topicName=帕金森病患者)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=a17f37322741, createdName=ms6832696159214430, createdTime=Wed Feb 08 21:53:01 CST 2023, time=2023-02-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2001831, encodeId=e1be200183100, content=<a href='/topic/show?id=d5df12695e6' target=_blank style='color:#2F92EE;'>#Neurol#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=96, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=12695, encryptionId=d5df12695e6, topicName=Neurol)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=8217292, createdName=yinhl1978, createdTime=Thu Sep 01 10:53:01 CST 2022, time=2022-09-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1225461, encodeId=d94b1225461f0, content=学习了,谢谢分享, beContent=null, objectType=article, channel=null, level=null, likeNumber=92, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=7c592194322, createdName=1209e435m98(暂无昵称), createdTime=Thu Jun 09 16:31:48 CST 2022, time=2022-06-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1573970, encodeId=eb2515e397040, content=<a href='/topic/show?id=6b3348526a0' target=_blank style='color:#2F92EE;'>#帕金森病患#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=117, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=48526, encryptionId=6b3348526a0, topicName=帕金森病患)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=73fe15977481, createdName=saikp, createdTime=Thu Jun 09 03:53:01 CST 2022, time=2022-06-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1604824, encodeId=dee9160482450, content=<a href='/topic/show?id=950f9419633' target=_blank style='color:#2F92EE;'>#运动症状#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=110, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=94196, encryptionId=950f9419633, topicName=运动症状)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=c33b19274468, createdName=sunrural_42825363, createdTime=Thu Jun 09 03:53:01 CST 2022, time=2022-06-09, status=1, ipAttribution=)]
  5. [GetPortalCommentsPageByObjectIdResponse(id=1757457, encodeId=60de1e5745767, content=<a href='/topic/show?id=058e4852e63' target=_blank style='color:#2F92EE;'>#帕金森病患者#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=114, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=48527, encryptionId=058e4852e63, topicName=帕金森病患者)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=a17f37322741, createdName=ms6832696159214430, createdTime=Wed Feb 08 21:53:01 CST 2023, time=2023-02-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2001831, encodeId=e1be200183100, content=<a href='/topic/show?id=d5df12695e6' target=_blank style='color:#2F92EE;'>#Neurol#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=96, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=12695, encryptionId=d5df12695e6, topicName=Neurol)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=8217292, createdName=yinhl1978, createdTime=Thu Sep 01 10:53:01 CST 2022, time=2022-09-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1225461, encodeId=d94b1225461f0, content=学习了,谢谢分享, beContent=null, objectType=article, channel=null, level=null, likeNumber=92, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=7c592194322, createdName=1209e435m98(暂无昵称), createdTime=Thu Jun 09 16:31:48 CST 2022, time=2022-06-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1573970, encodeId=eb2515e397040, content=<a href='/topic/show?id=6b3348526a0' target=_blank style='color:#2F92EE;'>#帕金森病患#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=117, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=48526, encryptionId=6b3348526a0, topicName=帕金森病患)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=73fe15977481, createdName=saikp, createdTime=Thu Jun 09 03:53:01 CST 2022, time=2022-06-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1604824, encodeId=dee9160482450, content=<a href='/topic/show?id=950f9419633' target=_blank style='color:#2F92EE;'>#运动症状#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=110, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=94196, encryptionId=950f9419633, topicName=运动症状)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=c33b19274468, createdName=sunrural_42825363, createdTime=Thu Jun 09 03:53:01 CST 2022, time=2022-06-09, status=1, ipAttribution=)]

相关资讯

iPSC疗法、新靶点、单细胞测序,帕金森病最新研究进展解读

帕金森病的治疗和诊断一直是十分热门的研究领域,最近帕金森病领域有了一些新的突破。通过这篇文章,我们一起了解下帕金森病领域的一些新发现、新进展。

Movement Disorders:路易体病理和阿尔兹海默病理,如何影响男女的临床表型差异?

使用LB和AD生物标志物,即使在LB或AD病理不在临床预期之内,对于LB疾病和AD的准确临床诊断也是必要的。

Movement Disorders:特发性帕金森病患者尿液中Rab10磷酸化的升高

pT73-Rab10的水平较高与疾病进展的恶化有关。

Movment Disorders:帕金森氏征,7T MRI蓝斑核完整性与帕金森病患者的冷漠和认知有关

去甲肾上腺素能治疗策略在解决神经退行性疾病的跨诊断认知和行为特征方面有潜力。

European Radiology:帕金森病的SMwI MRI前瞻性多中心研究

最近,临床上开发了感光图加权成像(SMwI)技术以改善描绘含铁结构的信噪比和对比度-噪声比。最近的研究进一步表明,SMwI在评估3T下的黑质高浓度方面优于SW。

拓展阅读

好文推荐 | 帕金森病、原发性震颤和神经元核内包涵体病的震颤特点

本研究进一步探讨PD、ET以及NIID震颤的表面肌电特点,为临床上三组疾病的鉴别提供客观的电生理指标。

Science:帕金森病的"分子帮凶"终现形:研究人员破解致病蛋白传播密码

FAM171A2是α-突触核蛋白纤维入侵神经元的关键受体,其基因变异与患病风险相关,操控该基因可改变病理进程,抗癌药bemcentinib或成治疗新靶点,为治疗带来希望。

Mol Psychiatry:环状RNA在神经系统疾病中的计算识别、功能验证及潜在临床应用

本文综述了circRNA在精神分裂症、双相情感障碍、重度抑郁症、阿尔茨海默病和帕金森病等神经系统疾病中的表达变化及其功能机制。circRNA通过调控miRNA和RNA结合蛋白,影响基因表达和突触功能。

Science:华山医院郁金泰团队首次发现帕金森病全新治疗靶点FAM171A2

近年来,随着全球人口老龄化加剧,帕金森病这一神经退行性疾病的发病率不断上升,已成为仅次于阿尔茨海默病的第二大常见神经退行性疾病,严重影响患者的运动功能和日常生活。全球帕金森病患病人数预计将从2015年

全球首次!复旦团队重磅Science:发现帕金森病全新治疗靶点,或可实现帕金森病“标本兼治”

该研究发现神经元FAM171A2介导α-突触核蛋白纤维摄取并驱动帕金森病。

Nature子刊:复旦大学郁金泰/程炜揭示了帕金森病新的病理生理学见解和潜在的生物标志物!

该研究利用帕金森病事件的大规模蛋白质组分析揭示了新的病理生理学见解和潜在的生物标志物。